RCMI Coordinating Center (RCMI CC) Header Logo

Connection

George Perry to Neurotransmitter Agents

This is a "connection" page, showing publications George Perry has written about Neurotransmitter Agents.
Connection Strength

0.760
  1. Plascencia-Villa G, Perry G. Status and future directions of clinical trials in Alzheimer's disease. Int Rev Neurobiol. 2020; 154:3-50.
    View in: PubMed
    Score: 0.717
  2. Manyevitch R, Protas M, Scarpiello S, Deliso M, Bass B, Nanajian A, Chang M, Thompson SM, Khoury N, Gonnella R, Trotz M, Moore DB, Harms E, Perry G, Clunes L, Ortiz A, Friedrich JO, Murray IVJ. Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers. Curr Alzheimer Res. 2018; 15(2):164-181.
    View in: PubMed
    Score: 0.038
  3. Whitehouse PJ, Gambetti P, Harik SI, Kalaria RN, Perry G, Younkin SI, Tabaton M, Unnerstall JR. Neurochemistry of dementia: establishing the links. Prog Clin Biol Res. 1989; 317:131-42.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support